Curbstone Financial Management Corp Invests $411,000 in Insulet Co. (NASDAQ:PODD)

Curbstone Financial Management Corp purchased a new position in shares of Insulet Co. (NASDAQ:PODD) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 1,764 shares of the medical instruments supplier’s stock, valued at approximately $411,000.

Several other large investors have also modified their holdings of the stock. Vanguard Group Inc. lifted its holdings in Insulet by 2.1% in the first quarter. Vanguard Group Inc. now owns 8,199,114 shares of the medical instruments supplier’s stock worth $1,405,328,000 after acquiring an additional 169,506 shares during the last quarter. Baillie Gifford & Co. lifted its holdings in Insulet by 30.8% in the second quarter. Baillie Gifford & Co. now owns 1,886,062 shares of the medical instruments supplier’s stock worth $380,607,000 after acquiring an additional 443,783 shares during the last quarter. Clearbridge Investments LLC lifted its holdings in Insulet by 6.0% in the second quarter. Clearbridge Investments LLC now owns 1,339,763 shares of the medical instruments supplier’s stock worth $270,364,000 after acquiring an additional 75,526 shares during the last quarter. William Blair Investment Management LLC lifted its holdings in Insulet by 3.7% in the first quarter. William Blair Investment Management LLC now owns 952,268 shares of the medical instruments supplier’s stock worth $163,219,000 after acquiring an additional 33,579 shares during the last quarter. Finally, American Century Companies Inc. lifted its holdings in Insulet by 18.7% in the second quarter. American Century Companies Inc. now owns 885,669 shares of the medical instruments supplier’s stock worth $178,728,000 after acquiring an additional 139,246 shares during the last quarter.

Insulet Price Performance

Insulet stock traded down $0.05 during mid-day trading on Friday, hitting $229.94. The company’s stock had a trading volume of 440,205 shares, compared to its average volume of 817,527. The company has a quick ratio of 2.71, a current ratio of 3.60 and a debt-to-equity ratio of 1.36. The stock has a market capitalization of $16.10 billion, a P/E ratio of 69.68, a P/E/G ratio of 4.34 and a beta of 1.21. Insulet Co. has a twelve month low of $125.82 and a twelve month high of $243.98. The stock’s fifty day moving average price is $209.88 and its two-hundred day moving average price is $192.02.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Thursday, August 8th. The medical instruments supplier reported $0.55 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.56 by ($0.01). The business had revenue of $488.50 million during the quarter, compared to analyst estimates of $488.00 million. Insulet had a return on equity of 30.73% and a net margin of 21.11%. The company’s quarterly revenue was up 23.2% compared to the same quarter last year. During the same quarter last year, the firm posted $0.38 EPS. Research analysts forecast that Insulet Co. will post 3.04 earnings per share for the current year.

Wall Street Analyst Weigh In

PODD has been the topic of a number of recent research reports. Piper Sandler raised their target price on shares of Insulet from $230.00 to $285.00 and gave the stock an “overweight” rating in a report on Tuesday, September 17th. BTIG Research cut their price target on Insulet from $270.00 to $250.00 and set a “buy” rating on the stock in a report on Friday, August 9th. Canaccord Genuity Group lifted their price target on Insulet from $236.00 to $269.00 and gave the company a “buy” rating in a report on Wednesday, September 25th. Barclays lifted their price target on Insulet from $200.00 to $220.00 and gave the company an “equal weight” rating in a report on Monday, August 12th. Finally, Citigroup lifted their price target on Insulet from $250.00 to $275.00 and gave the company a “buy” rating in a report on Tuesday. Four equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat, Insulet presently has an average rating of “Moderate Buy” and an average price target of $234.60.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.